Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

ELEKTA B

EKTAb.STSE0000163628NASDAQ StockholmSESEK
Stock price
ELEKTA B
Loading chart...

Coverage

Latest articles

Elekta outlines growth strategy, revises order backlog
11 Jun 2025, 19:27EKTAb.STNASDAQ Stockholm

Elekta AB detailed its future growth prospects and the results of a proactive order review at its Investor Update in Stockholm, the company said Tuesday.

Elekta revises order backlog down by 4.9 billion Swedish krona, targets 14% EBIT margin
10 Jun 2025, 09:03EKTAb.STNASDAQ Stockholm

Elekta announced a significant adjustment to its order backlog, cancelling orders valued at 4.9 billion Swedish Krona following a proactive review aimed at improving profitability and predictability.

Elekta names Jakob Just-Bomholt as new President and CEO
9 Jun 2025, 20:29EKTAb.STNASDAQ Stockholm

Elekta has appointed Jakob Just-Bomholt as its new President and CEO, effective September 1, 2025, the medical technology firm announced.

Elekta appoints Jakob Just-Bomholt as new president and CEO
9 Jun 2025, 20:26EKTAb.STNASDAQ Stockholm

Elekta announced Monday the appointment of Jakob Just-Bomholt as its new President and Chief Executive Officer, effective September 1, 2025.

Elekta appoints Jakob Just-Bomholt as new president and CEO
9 Jun 2025, 17:06EKTAb.STNASDAQ Stockholm

Elekta has named Jakob Just-Bomholt as its new President and Chief Executive Officer, effective September 1, 2025, the company announced.

Elekta reports mixed full-year results amid R&D impairment
8 Jun 2025, 20:30EKTAb.STNASDAQ Stockholm

Swedish medical technology firm Elekta reported a net loss of 381 million Swedish Kronor for its fourth quarter, impacted by a 1.064 billion Swedish Kronor non-cash impairment from discontinued research and development projects, the company said.

  • Previous
  • 1
  • 2

Filings

Recent filings

FilingDate
Elekta’s Nomination Committee for the 2017 Annual General Meeting9 Nov 2016
USITC publishes initial determination in litigation dispute31 Oct 2016
GenesisCare continues to expand Spanishcancer services with Elekta25 Oct 2016
All India Institute of Medical Science expands cancer care with advanced treatment devices from Elekta18 Oct 2016
Installation of Elekta’s sixth high-field MR-adaptive linear accelerator initiated at The Christie12 Oct 2016
Elekta and Brainlab improve interoperability and treatment capabilities in stereotactic neurosurgery treatments29 Sept 2016
Data presented at ASTRO underscore the promise of Elekta’s high-field MR-adaptive linear accelerator as a transformative advance in radiation therapy29 Sept 2016
Elekta’s new Leksell Vantage Stereotactic System improves imaging and workflow for neurosurgery procedures28 Sept 2016
Elekta informs investors of transformation program and advanced portfolio development at ASTRO Capital Markets presentation26 Sept 2016
Installation initiated for Elekta’s high-field MR-adaptive linear accelerator at Froedtert & the Medical College of Wisconsin Clinical Cancer Center20 Sept 2016
Reminder: Welcome to Elekta’s Capital Markets Presentation at ASTRO13 Sept 2016
Interim report May – July 2016/171 Sept 2016
  • Previous
  • 1
  • More pages
  • 18
Search
Company
ELEKTA B
EKTAb.STNASDAQ Stockholm
Website: Unavailable
Coverage
12
  • Next
  • 19
  • 20
  • More pages
  • 59
  • Next
  • Filings
    703